CClinicalTrials.gg
CompletedNCT05019469Updated Aug 24, 2021

Overcoming Gait Freeze in Parkinson's Disease Using Responsive Cueing

An interventional study of Rhythmic vibration cueing (lower leg) in Parkinson's Disease, sponsored by University of Oxford. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by University of Oxford · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Feb 2019, registered Aug 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of this pilot/feasibility study is to test if delivering rhythmic vibration cues to the lower legs, specifically in response to gait defects (rather than continuously), can improve walking quality and overcome gait freezing in Parkinson's disease.

During the study, people with Parkinson's disease that suffer from regular (daily) gait freezing will undertake a series of walking/activity circuits, receiving continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. Vibration cueing is provided by a non-invasive wearable device prototyped at the University of Oxford, worn on the lower legs during 3 circuits. A series of walking metrics will be analysed.

Read the detailed description

Parkinson's disease (PD) is a progressive, neurodegenerative disorder that impairs the ability to control movement. Gait freezing is an inability to walk spontaneously and continuously, and affects nearly half of PD patients, reducing quality of life and contributing to increased fall risk. Cueing (with visual, auditory or somatosensory stimuli) is an effective way to improve walking quality in people with PD. In this pilot study we aim to test if delivering rhythmic vibration cues acutely, specifically in response to gait defects, can improve walking quality and overcome gait freezing in PD.

During the study, people with PD that suffer from regular (daily) gait freezing, but who are able to stand and walk with minimal assistance, undertake 4 walking/activity circuits. During each of the circuits participants receive either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. Cueing is provided by a non-invasive wearable movement-tracking cueing device prototyped at the University of Oxford (approximately the size of a smart phone), worn on the lower legs during 3 circuits. The ordering of the interventions/circuits are systematically alternated for each participant. The impact of responsive cueing on walking ability can be determined by analysis of walking metrics across the circuits.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Gait freezing
  • Cueing
  • Gait
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 17 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University of Oxford is the lead sponsor of 794 studies on the registry; 117 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participant is willing and able to give informed consent for participation in the study.
  • Participant is fluent in English.
  • Participant is aged 18-90 years inclusive
  • Patients in whom the clinical diagnosis is stated as idiopathic Parkinson's disease or Parkinson's disease (PD).
  • Participant self-reports a history of daily gait freezing (several times a day), but should be able to stand and walk freely for short periods with minimal assistance.
  • Participant has no evidence for significant cognitive impairment.
  • In the investigator's opinion, is willing and able to comply with all trial requirements.

Exclusion criteria

Exclusion Criteria:

  • Participant has a medical or psychiatric illness that would interfere with completing initial and follow up assessments.
  • Participant has severe mental impairment, dementia or psychosis determined either by a prior diagnosis by a medical professional with relevant expertise, or by subjective assessment by the research team during the pre-study questionnaire (e.g. an inability to comprehend questions).
  • Active participation in a clinical drug trial.
  • Female who is pregnant, lactating or planning pregnancy during the course of the investigation. This information will be provided to us by the patient during recruitment screening.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Patients with frequent (daily) falls at home or out of home, or who demonstrate a high fall risk during the study.
  • Patients with atypical parkinsonism (eg MSA, PSP, CBD).
  • Patients who have had Deep Brain Stimulation for their PD.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Single arm of study

    Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.

    Device: Rhythmic vibration cueing (lower leg)

Interventions

  • DeviceRhythmic vibration cueing (lower leg)

    A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.

06

What researchers measure

Primary outcomes

  1. Step frequency

    The primary objective is to test if gait-freeze initiated vibration cues, provided at the lower-leg, can improve gait/walking quality in PD patients. The primary outcome measure will be cadence (step frequency) with other gait measurements including frequency and duration of gait freeze events, continuous walking time, left/right rhythm and stride length. Measurements extracted from video data collected during 1 hour study sessions. Change in these measurements assessed between cued (intervention) and no-cue (no intervention) walking circuits for each participant.

    Time frame: Data collected during 1 hour sessions up to study completion.

Secondary outcomes

  1. Automated gait freeze detection

    Generation of algorithms capable of recognising gait freeze events from device movement data with \>80% accuracy. Algorithm development to identify changes in accelerometer (g) and gyroscope (rsp) data from leg-worn devices indicative of gait freeze events. Algorithm accuracy expressed as % sensitivity and % specificity for identifying gait freeze events from movement data relative to observer time stamps.

    Time frame: Movement data collected during 1 hour sessions up to study completion.

07

Study locations

1 site
  • The Bosworth Clinic
    Cassington, Oxfordshire OX29 4DS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data points will be shown in the manuscript/publication reporting the study outcomes.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05019469
Lead sponsor
University of Oxford
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Feb 13, 2019
Primary completion
Jul 22, 2019
Completion
Jul 22, 2019
Last update
Aug 24, 2021

Study contacts

James Cantley, PhD
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion